anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the technical field of biological medicines, and particularly discloses a composition containing gamma-aminobutyric acid and probiotics active peptide and application thereof in preparation of products with anti-inflammatory effect. The probiotic active peptide has an amino acid sequence shown as SEQ ID NO. 1, SEQ ID NO. 2 or SEQ ID NO. 3; wherein, the amino acid sequence of SEQ ID NO. 1 is: thr-Glu-Trp-Ala-Glu; the amino acid sequence of SEQ ID NO. 2 is: thr-Gly-Glu-Pro; the amino acid sequence of SEQ ID NO. 3 is: thr-Glu-Gly-Phe-Ala. The composition containing gamma-aminobutyric acid and probiotic active peptide comprises gamma-aminobutyric acid and probiotic active peptide. The probiotic active peptide and the composition containing the gamma-aminobutyric acid and the probiotic active peptide have the effects of resisting inflammation and oxidization and improving the ultraviolet radiation injury resistance activity of cells; therefore, the active ingredient of the compound has important application prospect in preparing products with corresponding effects.
The vocal ligament is part of the layered structure of the vocal fold. It is a thin band of tissue near the superior medial edge of the vocal fold. The cord-like appearance of the ligament gave rise to the traditional term "vocal cord". The ligament connects the arytenoid cartilage (lower broad dark region) to the anterior portion of the thyroid cartilage (upper dark region). The slightly thickened endpoints are known as the anterior and posterior macula flava. In the medial-lateral direction, the vocal ligament comprises the intermediate and deep layer of the lamina propria.

The physiological functions of the vocal ligament are not fully understood. One function is to limit mechanical strain (elongation), a general function of most ligaments in the body. A second function may be to produce a firm closure of the glottis by forming a straight edge along the membranous (vibrating) portion of the vocal fold. A strong ligament that can be tensed with exercise is likely to help straighten the edge of the folds. Vocal fold bowing, for example, is a pathological condition often associated with advanced age, but it can also occur in young adults who press their arytenoid cartilages together excessively in speech. Atrophy of the thyroarytenoid muscle, which lies lateral to the ligament, causes the middle of the membranous vocal fold to be retracted from the midline of the glottis. The result is a weak voice because airflow cannot be suddenly shut off for efficient acoustic excitation of the vocal tract. For self-sustained vocal fold vibration, the superficial layer must be very pliable and deformable for mucosal surface-wave motion. The role of the ligament is then to stabilize the vertical motion when large pressures are applied to vocal fold surfaces. The most important known function of the ligament, however, is to widen the fundamental frequency range. The stiffer the ligament, the greater the likelihood that several octaves of fo range can be achieved.
Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
PURPOSE:To prepare the titled compound useful as an antiallergic agent, in high yield, by reacting a 2-styryl-3,1-benzoxazin-4-one derivative with an alkylating agent in the presence of a basic substance. CONSTITUTION:The objective compound of formula II (Y is 1-6C alkoxy) is prepared by reacting the 2-styryl-3,1-benzoxazin-4-one derivative of formula I (R1 and R2 are H or 1-3C alkyl; X is 1-6C alkoxy or OH; n is 0-2) with an alkylating agent (e.g. dialkyl sulfate) in the presence of a basic substance (e.g. NaOH). The reaction is carried out usually by using water or an organic solvent (e.g. acetone) as a reaction medium, adding the compound of formula I to an aqueous solution of somewhat excess sodium hydroxide, adding somewhat excess amount of dialkyl sulfate dropwise to the mixture under cooling and agitation, and reacting the components at room temperature or under heating for 1- ten odd hours.
Dextromethorphan: Dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties.

The drug acts centrally and elevates the threshold for coughing. It is about equal to codeine in depressing the cough reflex. In therapeutic dosage dextromethorphan does not inhibit ciliary activity.

Dextromethorphan is rapidly absorbed from the gastrointestinal tract and exerts its effect in 15 to 30 minutes. The duration of action after oral administration is approximately three to six hours. Dextromethorphan is metabolized primarily by liver enzymes undergoing O-demethylation, N-demethylation, and partial conjugation with glucuronic acid and sulfate. In humans, (+)-3-hydroxy-N-methyl-morphinan, (+)-3-hydroxymorphinan, and traces of unmetabolized drug were found in urine after oral administration.

Promethazine: Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of chlorpromazine) of dopamine antagonist properties.

Promethazine is an H1 receptor blocking agent. In addition to its antihistaminic action, it provides clinically useful sedative and antiemetic effects.

Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Promethazine is metabolized by the liver to a variety of compounds; the sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine.
1. A pharmaceutical composition containing as active agent at least one compound selected from the group consisting of: compound of formula (I)   and compound of formula (II)   and pharmaceutically acceptable acid in an amount, improving stability thereof. 2. The composition of Claim 1, wherein said pharmaceutically acceptable acid is selected from the group consisting of citric acid, glutamic acid, succinic acid, ethanesulfonic acid, acetic acid, tartric acid, ascorbic acid, methanesulfonic acid, fumaric acid, adipic acid, malic acid and mixtures thereof. 3. The composition of Claim 2, characterized in that it is solid dosage form wherein the active particles are granulated in the presence of a granulating agent to form granulated active solid particles. 4. The composition of Claim 2, characterized in that it is solid particles suspension of at least one of compounds of formula I and formula II in liquid. 5. The composition of Claim 4, wherein the liquid is water. 6. The composition of Claim 4, wherein the pH of said suspension is between 2 and 6. 7. The composition of Claim 4, wherein the pH of said suspension is between 3 and 5. 8. The composition of Claim 2, which is a paste, said paste comprising solid particles of at least one compounds of formula I and formula II, wetting agent and a thickener.
The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI 65-99 ), 142-169 (bBPI 142-169 ), or the combination of amino acids 90-99 and 148-161 (bBPI 90-99,148-161 ) of bBPI. The bBPI 90-99,148-161  peptide demonstrated the widest spectrum of antimicrobial activity, with minimum inhibitory (MIC) and bactericidal (MBC) concentration values ranging from 16-64 μg/ml against  Escherichia coli, Klebsiella pneumoniae , and  Enterobacter  spp, and 64-128 μg/ml against  Pseudomonas aeruginosa . None of the peptides exhibited any growth inhibitory effect on  Serratia marcescens . The antimicrobial activity of bBPI 90-99,148-161  was inhibited in milk, but preserved in serum. Finally, both bBPI 142-169  and bBPI 90-99,148-161  were demonstrated to completely neutralize LPS. The peptide bBPI 90-99,148-161  is a potent neutralizer of the highly pro-inflammatory molecule bacterial LPS and has antimicrobial activity against a variety of Gram-negative bacteria.
Prod. is obtd. by heating human plasma. The plasma used is pref. that of the patient. Fresh plasma is placed in an injection syringe and heated between 60 and 80 deg.C. The duration of heating may vary between 1 and 12 hours, sufficient heating being used to cause solidification of the plasma and, if desired, sterilisation of the product. Treatment of the product ultrasonically improves its fluidity. For certain applications, the fresh plasma may be separated into heavy molecules having a yellow appearance, and light molecules having a transparent appearance. These may then be recombined in any desired ratio, e.g. 70% light and 30% heavy, before heating. ADVANTAGE - The use of the prod. does not require surgery, unlike other breast enlargement and face-lifting methods.
The methods and compositions for prolonged alleviation of articular, synovia, and connective tissue joint pain include treatment solutions that are prepared and administered into the joint space or cavity of a painful (arthritic) or connective tissue target of the patient. The compositions include Procaine and at least two corticosteroids for providing prolonged alleviation of articular joint pain. A painful articular joint of a patient is positioned to facilitate the administration of the treatment solution into the joint or synovia space. The skin area over the joint space, is disinfected prior to the administration of the treatment solution. The administration of the treatment solution can be by injection with a syringe needle. Several different methods are provided for prolonged alleviation of pain of several different articular joints. The methods and compositions for prolonged alleviation of articular joint pain also can include kits for the treatment of such joint pain.
Laser acupuncture five times a week for a total of four weeks (20 sessions). Physical therapy three times a day, five times a week for a total of four weeks.
OBJECTIVE: Delta-like homolog 1 (DLK1) is a growth factor that is reduced in maternal sera in pregnancies with small for gestational age neonates. We sought to determine if DLK1 is associated with stillbirth (SB), with and without placental insufficiency.
STUDY DESIGN: A nested case-control study was performed using maternal sera from a multicenter case-control study of SB and live birth (LB). SB and LB were stratified as placental insufficiency cases (small for gestational age <5% or circulatory lesions on placental histopathology) or normal placenta controls (appropriate for gestational age and no circulatory lesions). Enzyme-linked immunosorbent assay (ELISA) was used to measure DLK1. The mean difference in DLK1 was compared on the log scale in an adjusted linear regression model with pairwise differences, stratified by term/preterm deliveries among DLK1 results in the quantifiable range. In exploratory analysis, geometric means were compared among all data and the proportion of "low DLK1" (less than the median value for gestational age) was compared between groups and modeled using linear and logistic regression, respectively.
RESULTS: Overall, 234 SB and 234 LB were analyzed; 246 DLK1 values were quantifiable within the standard curve. Pairwise comparisons of case and control DLK1 geometric means showed no significant differences between groups. In exploratory analysis of all data, adjusted analysis revealed a significant difference for the LB comparison only (SB: 71.9 vs. 99.1 pg/mL, p = 0.097; LB: 37.6 vs. 98.1 pg/mL, p = 0.005). In exploratory analysis of "low DLK1," there was a significant difference between the odds ratio of having "low DLK1" between preterm cases and controls for both SB and LB. There were no significant differences in geometric means nor "low DLK1" between SB and LB.
CONCLUSION: In exploratory analysis, more placental insufficiency cases in preterm SB and LB had "low DLK1." However, low DLK1 levels were not associated with SB.
KEY POINTS: · Maternally circulating DLK1 is correlated with placental insufficiency.. · Maternally circulating DLK1 is not correlated with SB.. · DLK1 is a promising marker for placental insufficiency..
The invention discloses a chalcone phenazine hybrid molecule and application thereof, in particular application of the hybrid molecule as an iron death inducer in resisting brain glioma. The invention synthesizes a series of novel phenazine compounds (C1-C13) containing chalcone skeletons through CuAAC click reaction. Part of the compounds have selective cytotoxic effects on U87-MG cells in vitro, wherein the antiproliferative activity of the compound C4 is the strongest. The compound C4 can induce U87-MG cell iron death as shown by transcription, lipid peroxidation and lipid ROS detection. Transcription results indicated that solute carrier family 7 member 11 (SLC 7a 11) expression was up-regulated, while GPX4 and ferritin heavy chain 1 (FTH 1) expression was down-regulated. Immunoblot analysis showed that ferritin was significantly degraded after compound C4 treatment. The invention provides a new cell iron death inducer, and also provides a new idea and method for treating brain glioma.
The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
The aim of this study was to investigate the epicardial adipose tissue thickness (EATT) and the related factors in patients with ankylosing spondylitis (AS) and to compare the results with those of the healthy controls. This cross-sectional study comprised thirty patients diagnosed with AS based on the modified New York criteria. The control group consisted of 31 healthy volunteers. Demographic characteristics were recorded. EATT was measured via transthoracic echocardiography. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life (ASQoL), International Physical Activity Questionnaire Short Form (IPAQ-Short Form) were used. Functional capacity assessment was conducted using the six-minute walk test (6MWT).
The patient (or parent/caregiver) should be instructed to seek medical advice whenever nausea, vomiting, persistent headache, insomnia or rapid heartbeat occurs during treatment with theophylline, even if another cause is suspected. The patient should be instructed to contact their healthcare professional if they develop a new illness, especially if accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another healthcare professional adds a new medication or discontinues a previously prescribed medication. Patients should be informed that theophylline interacts with a wide variety of drugs (see Table II). The dietary supplement St. John’s Wort (Hypericum perforatum) should not be taken at the same time as theophylline, since it may result in decreased theophylline levels. If patients are already taking St. John’s Wort and theophylline together, they should consult their healthcare professional before stopping the St. John’s Wort, since their theophylline concentrations may rise when this is done, resulting in toxicity. Patients should be instructed to inform all healthcare professionals involved in their care that they are taking theophylline, especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their healthcare professional. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.

Uniphyl® Tablets can be taken once a day in the morning or evening. It is recommended that Uniphyl be taken with meals. Patients should be advised that if they choose to take Uniphyl with food it should be taken consistently with food and if they take it in a fasted condition it should routinely be taken fasted. It is important that the product whenever dosed be dosed consistently with or without food.

Uniphyl Tablets are not to be chewed or crushed because it may lead to a rapid release of theophylline with the potential for toxicity. The scored tablet may be split. Patients receiving Uniphyl Tablets may pass an intact matrix tablet in the stool or via colostomy. These matrix tablets usually contain little or no residual theophylline.
Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)\* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
No intervention will be applied to women. Posttest application to women; It will be conducted online 8 weeks after the pre-test application. RLS Severity Rating Scale form, Johns Hopkins Restless Legs Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used in the pre-test and post-test applications.
The study will be a 4 week, parallel-group double blind randomised control trial of the efficacy pf Omega-3 as an augmentor of antidepressant treatment for depression. People aged between 18 and 65 with a first or new episode of depression warranting treatment with antidepressant medication will be recruited. In addition to their antidepressant medication, participants will be randomly allocated to receive either Omega-3 (fish oil) or placebo (paraffin oil)for 4 weeks. Participants will commence treatment with the antidepressant and Omega-3/placebo simultaneously. Participants will be followed up at 1,3 and 4 weeks and will be asked to rate their mood daily for the 4 week study period. Blood samples will be taken pre and post treatment to measure change in Omega-3 levels.
The current study examined associations between parental adversities as experienced in adolescence and hair cortisol concentration (HCC) 26 years later (n = 47). Specifically, bivariate correlations and linear regressions were used to examine harsh parenting as well as parental economic pressure, emotional distress, and body mass index (BMI) when their adolescent was between 15 and 16 years old (parent average age 43). HCC was measured when the adolescent was an adult (average 42 years old), at a similar age to when their parent(s) first participated in the study. We also assessed their economic pressure, emotional distress, obesity, and perceived stress in adulthood. For results across generations, parental economic pressure experienced during adolescence was significantly related to HCC when these adolescents were adults. None of the adult economic pressure, emotional distress, BMI, and perceived stress variables were associated with their HCC. Interestingly, there were significant associations among adult perceived stress, economic pressure, emotional distress, and obesity. Thus, the association between parental economic pressure and adult HCC is independent of adult adversities. Results highlight early economic adversity as a possible childhood stressor that has implications throughout the life course.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel derivatives of N-substituted 3-azabicyclo-[3.2.0]-heptane of the formula (I)   where R 1  is naphthyl or phenanthryl group that can be substituted with halogen atoms; n = 1-4; R 2  is C 1-4 -alkyl group or in common with adjacent carbon atom it means carbonyl group; X and Y are carbon atoms, N-alkyl C 1-4 -groups, -NH- or nitrogen atoms; Z means direct bond, carbonyl or CH-group; A is C 1-4 -alkylamino-group or in common with Y it is a part of condensed thiazole, pyridine or benzene ring that can be substituted with chlorine or fluorine atoms and their salts with physiologically acceptable acids. These compounds show antipsychotic activity. Invention relates to pharmaceutical compositions based on these compounds also. EFFECT: new compounds indicated above, valuable medicinal properties. 3 cl, 1 tbl, 10 ex
INTRODUCTION: Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS).
METHODS: CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry evaluating platelet inhibition in patients with MI. We examined the duration of cangrelor infusion and the amount of time to transition from cangrelor to an oral P2Y12 inhibitor in patients with CS. We also assessed major adverse cardiovascular events (MACEs) and bleeding risks, stratified by dosage duration, time to transition and oral P2Y12 inhibitor potency.
RESULTS: Among 2352 cangrelor-treated patients with MI, 249 patients were in CS. Among the patients with CS, 16 (6.4%) received the "bridge" infusion dose, 202 (81.1%) the PCI cangrelor infusion dose, and 30 (12.0%) had a combination of both infusion doses. Patients with CS had a median age of 66 years; 32% were women; 21% were Black patients; 35% had diabetes; 19% received thrombectomy; and 59% received mechanical circulatory support (MCS) (35% intra-aortic balloon pump, 27% Impella). The median duration of infusion was 3.9 (2-21.5 hours) in patients with CS and was 2 (1.6-3.1 hours) for all cangrelor-treated patients. The median duration of transition from cangrelor to oral P2Y12 inhibitor administration was 0.1 (-0.5-21.0 hours) for patients with CS. In multivariable modeling, chronic lung disease and the use of MCS and was associated with longer cangrelor infusions (defined as > 3.9 hours). Among cangrelor-treated patients with CS, 24.1% of these patients had a bleeding event, and 41.8% had a MACE event. After adjustment, a longer cangrelor infusion duration was associated with increased risk of bleeding (P < 0.05).
CONCLUSIONS: The median duration of cangrelor infusion was longer for patients presenting with CS. Use of MCS was associated with longer cangrelor infusion durations in patients with CS. Further work is needed to understand the pharmacodynamics of antiplatelet agents in patients with CS.
The spray bottle provides nasal enrichment of a defensive agent to patients exposed to poisoning. Its spray valve contains a metering device delivering an exact amount of the agent via a nasal adapter. The storage vessel can be of plastic-coated glass, with a capacity between 5 and 30ml, while the metering valve can be arranged to deliver doses of between 0.01-0.20ml. The agent used can be an alcoholic soln. of free atropine base. USE - Partic. for victims of chemical warfare or pesticides.